Immunotherapy for Lung Cancer

Basit Öğe Kaydı
dc.authorscopusid23567989600
dc.authorscopusid6701376935
dc.authorscopusid7004153441
dc.authorscopusid6701400454
dc.authorscopusid55550154500
dc.authorscopusid57196215937
dc.authorscopusid55892938700
dc.contributor.authorKaradurmus, N.
dc.contributor.authorAkyürek, N.
dc.contributor.authorAydiner, A.
dc.contributor.authorSavaş, R.
dc.contributor.authorSönmez, Ö.
dc.contributor.authorSendur, M.A.N.
dc.contributor.authorOyan, B.
dc.date.accessioned2024-08-25T18:51:45Z
dc.date.available2024-08-25T18:51:45Z
dc.date.issued2023
dc.departmentEge Üniversitesien_US
dc.description.abstractLung cancer is one of the leading causes of cancer-related deaths in men and women. Similar to the approach with other cancer types, lung cancer staging is crucial in planning an effective treatment plan and predicting patient prognosis. Effective immunotherapies for patients with non-small cell lung cancer and non-genomic driver mutations are rapidly evolving. Moreover, anti-programmed death re-ceptor-1 (PD-1)/programmed death ligand 1 (PD-L1)-based treatments have become the first-line standard of care. Despite shortcomings, PD-L1 expression level seems currently to be a relatively reliable predictor of the clinical efficacy of treatment with anti-PD-1/PD-L1 anti-bodies. However, additional biomarkers are required to better personalize treatment options for these patients. This review aimed to increase awareness of lung cancer and immunotherapy treatment options, depending on patient and disease stage characteristics. © 2023 by Turkish Society of medical oncology.en_US
dc.description.sponsorshipBristol-Myers Squibb, BMSen_US
dc.description.sponsorshipThis work was supported by Bristol Myers Squibb, İstanbul, Türkiye.en_US
dc.identifier.doi10.37047/jos.2022-92712
dc.identifier.endpage111en_US
dc.identifier.issn2651-4532
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85169791072en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage97en_US
dc.identifier.urihttps://doi.org/10.37047/jos.2022-92712
dc.identifier.urihttps://hdl.handle.net/11454/102703
dc.identifier.volume9en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTurkiye Kliniklerien_US
dc.relation.ispartofJournal of Oncological Scienceen_US
dc.relation.publicationcategoryDiğeren_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240825_Gen_US
dc.subjectBiomarkeren_US
dc.subjectimmune checkpoint inhibitoren_US
dc.subjectimmunotherapyen_US
dc.subjectmutationen_US
dc.subjectnon-small cell lung canceren_US
dc.titleImmunotherapy for Lung Canceren_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu